Slideshow

Antibody Testing in Patients With Neurological and Psychiatric Symptoms

Author(s):

Veronica Hackethal, MD

New research may help doctors determine when (and when not) to test for antiglutamate decarboxylase antibodies in patients with neurological disorders and psychiatric symptoms.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!
Related Videos
Satyanarayana Gedela, MD
Satyanarayana Gedela, MD
Related Content
Ana Suller Marti, MD (Credit: Suller Marti Lab)
July 9th 2025

LivaNova’s VNS Therapy Maintains Effectiveness in Drug-Resistant Epilepsy in Latest 2-Year Data

Isabella Ciccone, MPH
Episode 144: Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead
June 27th 2025

Episode 144: Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead

Marco Meglio Joseph Sullivan, MD
Most Impactful Neurology Trial Readouts From Early 2025
June 30th 2025

Most Impactful Neurology Trial Readouts From Early 2025

Marco Meglio Isabella Ciccone, MPH
Episode 141: Refining TSC Care: Phenotyping, Clustering, and Clinical Impact
May 16th 2025

Episode 141: Refining TSC Care: Phenotyping, Clustering, and Clinical Impact

Marco Meglio Ajay Gupta, MD
Veronica Hood, PhD (Credit: Dravet Syndrome Foundation)
June 23rd 2025

The Changing Landscape of Dravet Syndrome

Veronica Hood, PhD
FDA Action Update, May 2025: Approval, Clearance, and Authorization
June 10th 2025

FDA Action Update, May 2025: Approval, Clearance, and Authorization

Isabella Ciccone, MPH
© 2025 MJH Life Sciences

All rights reserved.